NEPH vs. PYPD, IINN, GCTK, AKLI, SSKN, MHUA, ICU, PAVM, FEMY, and TTOO
Should you be buying Nephros stock or one of its competitors? The main competitors of Nephros include PolyPid (PYPD), Inspira Technologies Oxy B.H.N. (IINN), GlucoTrack (GCTK), Akili (AKLI), STRATA Skin Sciences (SSKN), Meihua International Medical Technologies (MHUA), SeaStar Medical (ICU), PAVmed (PAVM), Femasys (FEMY), and T2 Biosystems (TTOO). These companies are all part of the "surgical & medical instruments" industry.
PolyPid (NASDAQ:PYPD) and Nephros (NASDAQ:NEPH) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, community ranking, earnings, dividends, analyst recommendations, valuation and media sentiment.
26.5% of PolyPid shares are held by institutional investors. Comparatively, 41.1% of Nephros shares are held by institutional investors. 24.7% of PolyPid shares are held by company insiders. Comparatively, 4.1% of Nephros shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
PolyPid has a net margin of 0.00% compared to PolyPid's net margin of -11.06%. PolyPid's return on equity of -18.25% beat Nephros' return on equity.
PolyPid received 10 more outperform votes than Nephros when rated by MarketBeat users. Likewise, 72.41% of users gave PolyPid an outperform vote while only 39.29% of users gave Nephros an outperform vote.
PolyPid has a beta of 1.41, suggesting that its share price is 41% more volatile than the S&P 500. Comparatively, Nephros has a beta of 1.3, suggesting that its share price is 30% more volatile than the S&P 500.
Nephros has higher revenue and earnings than PolyPid. Nephros is trading at a lower price-to-earnings ratio than PolyPid, indicating that it is currently the more affordable of the two stocks.
In the previous week, PolyPid and PolyPid both had 3 articles in the media. PolyPid's average media sentiment score of 0.71 beat Nephros' score of 0.00 indicating that Nephros is being referred to more favorably in the news media.
Summary
PolyPid and Nephros tied by winning 7 of the 14 factors compared between the two stocks.
Get Nephros News Delivered to You Automatically
Sign up to receive the latest news and ratings for NEPH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NEPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
